• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan

by | May 1, 2024 | Publications

Int J Clin Oncol. 2024 Apr 30. doi: 10.1007/s10147-024-02531-1. Online ahead of print. NO ABSTRACT PMID:38687406 | DOI:10.1007/s10147-024-02531-1

T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma

by | May 1, 2024 | Publications

Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-3333. Online ahead of print. ABSTRACT PURPOSE: Bispecific antibodies (BsAbs) directed against B-cell maturation antigen (BCMA; teclistamab) or the orphan G protein-coupled receptor GPRC5D (talquetamab) induce...

Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach

by | May 1, 2024 | Publications

Leukemia. 2024 Apr 30. doi: 10.1038/s41375-024-02247-1. Online ahead of print. NO ABSTRACT PMID:38688994 | DOI:10.1038/s41375-024-02247-1

Complex Pathological Femoral Fracture in a Multiple Myeloma Patient Undergoing Intertrochanteric Fixation: A Case Report

by | May 1, 2024 | Publications

Cureus. 2024 Apr 14;16(4):e58224. doi: 10.7759/cureus.58224. eCollection 2024 Apr. ABSTRACT Pathological fractures commonly occur in patients with metastatic bone diseases, particularly multiple myeloma. The current optimal management for metastatic pathological...

A comparative analysis of transcriptomics of newly diagnosed multiple myeloma: exploring drug repurposing

by | May 1, 2024 | Publications

Front Oncol. 2024 Apr 16;14:1390105. doi: 10.3389/fonc.2024.1390105. eCollection 2024. ABSTRACT Multiple myeloma (MM) is an incurable malignant plasma cell disorder characterized by the infiltration of clonal plasma cells in the bone marrow compartment. Gene...

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

by | Apr 30, 2024 | Publications

BMC Cancer. 2024 Apr 29;24(1):541. doi: 10.1186/s12885-024-12263-0. ABSTRACT OBJECTIVES: The goal of the research was to assess the quantitative relationship between median progression-free survival (PFS) and median overall survival (OS) specifically among patients...
« Older Entries
Next Entries »

Recent Content

  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT